Evidence map›Paper›PMID 31278420›Full record

ArticleCellular and molecular life sciences : CMLS2020

Purinergic P2Y

Severin Mühleder, Christiane Fuchs, José Basílio, Dorota Szwarc, Karoline Pill, Krystyna Labuda, Paul Slezak, Christian Siehs, Johannes Pröll, Eleni Priglinger and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Antimicrobial Peptide Signaling in Skin Diseases.JID innovations : skin science from molecules to population health · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Severin MühlederLudwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria.
Christiane FuchsAustrian Cluster for Tissue Regeneration, Vienna, Austria.
José BasílioDepartment of Vascular Biology and Thrombosis Research, Medical University of Vienna, Vienna, Austria.
Dorota SzwarcAustrian Cluster for Tissue Regeneration, Vienna, Austria.
Karoline PillLudwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria.
Krystyna LabudaLudwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria.
Paul SlezakLudwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria.
Christian SiehsMag. Dipl.-Ing. Dr. Christian Siehs, IT-Services, GLN 9110002040261, Vienna, Austria.
Johannes PröllAustrian Cluster for Tissue Regeneration, Vienna, Austria.
Eleni PriglingerLudwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria.
Carsten HoffmannInstitut für Molekulare Zellbiologie, CMB-Center for Molecular Biomedicine, Universitätsklinikum Jena, Friedrich-Schiller-Universität, Jena, Germany.
Wolfgang G JungerLudwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria.
Heinz RedlLudwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria.
Wolfgang HolnthonerLudwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria. wolfgang.holnthoner@trauma.lbg.ac.at.ORCID http://orcid.org/0000-0001-6425-9028
Ludwig Boltzmann Institute for Traumatology, The Research Center in Cooperation with AUVA · ATUniversity of Applied Sciences Technikum Wien · ATBeth Israel Deaconess Medical Center · USJena University Hospital · DEJohannes Kepler University of Linz · ATMedical University of Vienna · AT

Funding

Interreg ATCZ133
6 · The paper itself

Abstract

Purinergic P2 receptors are critical regulators of several functions within the vascular system, including platelet aggregation, vascular inflammation, and vascular tone. However, a role for ATP release and P2Y receptor signalling in angiogenesis remains poorly defined. Here, we demonstrate that blood vessel growth is controlled by P2Y

Indexed as

Angiopoietin-2Antigens, CD34Cells, CulturedEndothelial CellsEndothelium, VascularHumansMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Neovascularization, PhysiologicPhosphorylationPlatelet AggregationPurinergic P2Y Receptor AntagonistsReceptors, CXCR4Receptors, Purinergic P2Y2RNA InterferenceRNA, Small InterferingAngiopoietin-2Antigens, CD34CXCR4 protein, humanKDR protein, humanMAPK1 protein, humanMAPK3 protein, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Purinergic P2Y Receptor AntagonistsReceptors, CXCR4Receptors, Purinergic P2Y2RNA, Small InterferingVascular Endothelial Growth Factor Receptor-2AngiogenesisEndothelialP2Y2PurinergicSproutingTip cell

Identifiers

PMID31278420
PMCPMC11104991
OpenAlexW2954702755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.